Foley Hoag LLP advised Dicerna Pharmaceuticals, Inc. on the transaction
Dicerna entered into a collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNA interference therapies for complement-mediated diseases.
Dicerna Pharmaceuticals, Inc. provides biopharmaceutical products. The Company, led by Douglas M Fambrough III, John B Green and James B Weissman, discovers and develops ribonucleic acid for the treatment of liver diseases and cancer. In 2017 the company recorded $2.3 Million revenues.
Foley Hoag advised Dicerna with team of Hemmie Chang (Picture), Karen Tepichin and Mark Potash
Law Firms: Foley Hoag;
Clients: Dicerna Pharmaceuticals, Inc. ;